Otto Warburg published his Nobel lecture in 1931 and said, with the directness that won him the prize:
“Cancer, above all other diseases, has countless secondary causes. But, even for cancer, there is only one prime cause.
Summarized in a few words, the prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar.”
For forty years, his work was the leading framework for understanding cancer.
Then the genetic mutation theory emerged. Oncogenes. Tumour suppressor genes. DNA damage. The molecular biology of cancer became the dominant research paradigm from the 1970s onward.
Warburg’s metabolic theory was not disproven. It was superseded by a framework that had more funding and more pharmaceutical applications.
The problem: the genetic mutation theory has driven cancer research and treatment for fifty years. The outcomes have been mixed. For some cancers: certain leukaemias, some lymphomas, targeted therapies have been transformative. For solid tumours, the majority of cancer burden, five-year survival rates have improved modestly in many cases, barely at all in others.
Meanwhile, Thomas Seyfried at Boston College has published extensively arguing that cancer’s genetic mutations are downstream of metabolic dysfunction: that the mitochondrial impairment Warburg identified is the primary event, and that the mutations are a consequence, not the cause.
His book “Cancer as a Metabolic Disease” (2012) is one of the most important unread books in oncology.
The practical implications if Seyfried and the neo-Warburgian school are right:
Starving tumours of glucose, through therapeutic ketosis, directly targets their primary metabolic vulnerability.
Providing ketones as an alternative fuel gives normal cells a metabolic advantage over cancer cells, which largely cannot use them.
The combination of caloric restriction and ketogenic diet has shown striking results in animal models.
Human case reports of tumour regression on ketogenic protocols as adjuncts to standard treatment are documented.
The therapy requires no patent.
It requires food choices.
It may be most effective in combination with standard treatment.
The research funding to test it properly has not materialised.
Nobody is getting rich from telling cancer patients to stop eating sugar and start eating beef.
The people getting rich are selling the glucose-based IV nutrition that goes into cancer patients in hospitals, the corticosteroids that raise blood glucose, and the drugs that manage the disease rather than the environment in which it thrives.
Warburg was right in 1924.
The evidence that he was right has been accumulating for a century.
The clinical application has not followed the evidence.
The clinical application follows the money.
Every time.
Source: https://x.com/SamaHoole/status/2026690777749844257?s=20
Waking Giant News 